Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease

BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell h...

Full description

Bibliographic Details
Main Authors: Christopher Cronin, Ronan McLaughlin, Louise Lane, Francesca M. Brett, Michael Jansen, Niamh Bermingham, Gerald Wyse, Liam Grogan, Patrick G. Morris, Seamus O’Reilly
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Medicine
Subjects:
BRAF
CNS tumors
brain tumor
glioma
Rosai-Dorfman disease
BRAF-inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1070828/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1070828/full

Similar Items